Posterior column ataxia-retinitis pigmentosa syndrome

Posterior column ataxia with retinitis pigmentosa, abbreviated PCARP, is an autosomal recessive neurodegenerative disorder in which progressive degeneration of the dorsal columns of the spinal cord and of the retina produces sensory ataxia and blindness.

It belongs to the small family of FLVCR1-related disorders, begins in childhood with areflexia, proprioceptive loss and night blindness, and has been reported in only about twenty patients over the past half century, so most clinicians never see a case.

Terminology and classification

• The standard name is posterior column ataxia with retinitis pigmentosa, abbreviated PCARP, and Orphanet lists the synonyms autosomal recessive posterior column ataxia and retinitis pigmentosa and retinopathy-sensory neuropathy syndrome under ORPHA:88628.
• ICD-10 places the disorder at G11.1, early-onset cerebellar ataxia, a grouping that is clinically inaccurate because the ataxia is sensory rather than cerebellar, while ICD-11 groups it inside the hereditary ataxia block 8A03 without a dedicated disease-specific stem code.
• Ontology identifiers are MONDO:0012177, OMIM 609033, UMLS C1836916, MeSH C536343, GARD 9898 and Wikidata Q55345797, which together anchor the disease across clinical, genetic and bibliographic databases.
• PCARP is one phenotype of biallelic FLVCR1 variation, a spectrum that also includes isolated retinitis pigmentosa and hereditary sensory and autonomic neuropathy, and a 2024 series extended it further to severe developmental disorders.
• The phrase posterior column refers to the dorsal columns of the spinal cord that carry proprioceptive and vibratory sensation, and damage there explains why patients lose position sense long before they lose muscle power.
• Orphanet classifies the disorder as rare with a prevalence below one per million and an autosomal recessive mode of inheritance, and it is not included in the Chinese national rare disease catalogue of 2018 or 2023.

History

• In 1997 Higgins and colleagues described an autosomal recessive family from the United Kingdom in whom posterior column ataxia and retinitis pigmentosa segregated together, and this report defined the clinical entity that became known as PCARP.
• In 2010 Rajadhyaksha and colleagues used targeted capture and high-throughput sequencing of chromosome 1q32 to identify biallelic FLVCR1 mutations in the original family, and they reported at least eleven distinct variants in subsequent series.
• FLVCR1 had been characterised in 2004 as a heme exporter essential for erythroid development, so the discovery that its loss causes retinal and spinal cord degeneration linked PCARP to heme trafficking rather than to a classic ataxia gene.
• Work published in 2021 and 2022 showed that FLVCR1 also transports choline and ethanolamine, which revised the mechanistic picture from a pure heme-exporter model to a dual role in membrane phospholipid synthesis.
• A 2024 international collaboration widened the phenotype to include severe developmental disorders with fetal akinesia and arthrogryposis, showing that the same gene can produce disease ranging from adult neurodegeneration to perinatal lethality.
• Orphanet's 2011 entry recorded about twenty cases in fifty years, and subsequent case reports from Italy, Turkey, Japan and Korea have added only a handful, so the literature remains dominated by single families.

Epidemiology

• Orphanet gives a prevalence class below one per one million, and the total published experience is about twenty patients over fifty years, making PCARP one of the rarest hereditary ataxias.
• Onset is in childhood in the great majority of reported patients, and the earliest signs are usually areflexia and night blindness rather than gait disturbance, which delays recognition until walking becomes unstable.
• Inheritance is autosomal recessive, and pseudodominant transmission has been documented when a heterozygous carrier parent mates with an affected homozygous partner, a pattern that can mislead family studies.
• Reported families originate from the United Kingdom, Italy, Turkey, Japan and Korea, and consanguinity is a recurring feature in pedigrees from the eastern Mediterranean and East Asia.
• No sex predilection has been established, and the small number of cases means that age-specific incidence, carrier frequency and population prevalence remain unmeasured.
• The disorder is probably underdiagnosed because isolated retinitis pigmentosa and isolated sensory neuropathy are common referral labels, and FLVCR1 is seldom included in first-tier retinal dystrophy panels.
• Natural history series indicate that walking ability and vision are lost after ten to thirty years of progression, so most patients become wheelchair dependent and blind in adult life.
• Named data sources are the Orphanet report updated in 2011, the OMIM entry 609033, the 2024 biallelic FLVCR1 cohort and the European Reference Network for rare neurological diseases, which lists PCARP among its covered ataxias.

Pathophysiology

• FLVCR1 lies at chromosome 1q32.3 and encodes the feline leukaemia virus subgroup C receptor 1, a twelve-transmembrane protein that exports heme from the cytosol and protects cells from heme toxicity.
• Loss of FLVCR1 function is thought to cause heme accumulation in neurons and photoreceptors, triggering oxidative stress, mitochondrial injury and progressive cell death in the dorsal columns and outer retina.
• The later discovery that FLVCR1 also imports choline and ethanolamine suggests that defective phospholipid synthesis contributes to membrane instability in the same tissues, which may explain the retinal and neural selectivity.
• Pathology centres on Wallerian-like degeneration of the dorsal columns with relative sparing of the corticospinal and spinothalamic tracts, while the cerebellum and cerebral cortex remain structurally normal.
• Biallelic missense variants that retain partial transport activity tend to produce a later, purer retinal phenotype, whereas truncating variants are associated with earlier sensory neuropathy and more severe disability.
• The combination of posterior column loss and photoreceptor degeneration explains the two signature modalities, proprioception and vision, that deteriorate in parallel throughout the disease course.

Clinical features

• Sensory ataxia is the defining neurological feature, with loss of vibration and position sense, a positive Romberg sign, wide-based gait and absent ankle and knee reflexes.
• Proprioceptive loss is described over the iliac crests, upper limbs and thorax, an unusual distribution that reflects damage to the cervical and thoracic dorsal columns rather than to peripheral nerves alone.
• Retinitis pigmentosa begins with night blindness and concentric visual field constriction, progresses to bone-spicule pigmentation and optic disc pallor, and often ends in legal blindness.
• Muscle weakness and atrophy appear later and are most marked distally, while severe scoliosis and camptodactyly of the fingers are recurrent skeletal findings in published families.
• Achalasia and gastrointestinal motility dysfunction are recognised associations, and they can cause dysphagia, regurgitation and weight loss that require separate gastroenterological management.
• Named complications include falls and fractures from ataxia, contractures from camptodactyly, aspiration from achalasia, depression from progressive blindness and complete loss of independent walking.

Diagnosis

• Diagnosis is suspected from childhood sensory ataxia with areflexia and a pigmentary retinopathy, and confirmed by identifying biallelic pathogenic FLVCR1 variants on sequencing.
• Spinal MRI shows atrophy of the cord and increased signal in the dorsal columns, whereas brain MRI is usually normal, a pattern that helps separate PCARP from cerebellar and cerebral ataxias.
• Nerve conduction studies show a length-dependent sensory axonal neuropathy with normal motor conduction, and electromyography is usually normal apart from late distal denervation.
• Ophthalmological assessment combines fundoscopy, full-field electroretinography and visual field testing, and electroretinography shows a reduced or extinguished response before the fundus becomes visibly abnormal.
• The differential includes Friedreich ataxia with FXN repeat expansion, subacute combined degeneration from vitamin B12 deficiency, tabes dorsalis, PHARC from ABHD12 mutations and other autosomal recessive ataxias such as ARSACS.
• Vitamin B12, copper, vitamin E, very long chain fatty acids and thyroid function are checked to exclude treatable mimics before a genetic diagnosis is accepted, because several of them also cause sensory ataxia with retinopathy.
• Diagnostic delay is common because night blindness is attributed to a primary retinal dystrophy and the neurological signs are mild for years, so a combined neuro-ophthalmological assessment shortens the interval to testing.
• No newborn screening programme or biochemical biomarker exists, and carrier testing is offered only to relatives of a confirmed proband within genetic counselling.

Management

• There is no approved disease-modifying therapy, so management is multidisciplinary and directed at preserving mobility, vision and nutrition while preventing complications.
• Physiotherapy focuses on balance, proprioceptive training and gait aids, and occupational therapy addresses falls prevention, home adaptation and upper limb function as the disease progresses.
• Vision rehabilitation includes low vision aids, orientation and mobility training, braille and screen-reader instruction, and certification of visual impairment for social support.
• Achalasia is managed by pneumatic balloon dilation, botulinum toxin injection or Heller myotomy, and nutritional support is added when dysphagia causes weight loss.
• Scoliosis is monitored with serial radiographs and treated with bracing or spinal fusion when the curve progresses, while camptodactyly is managed by stretching and splinting rather than surgery.
• Genetic counselling covers the 25 percent recurrence risk for siblings of an affected child, carrier testing of relatives, prenatal diagnosis and preimplantation genetic testing for families who request it.
• Surveillance should include annual neurological assessment, ophthalmological review with electroretinography, spinal imaging for scoliosis and swallowing assessment when dysphagia emerges.
• Prognosis is progressive, with loss of independent walking and useful vision typically after ten to thirty years, and no drug has been shown to slow either the retinal or the spinal component.

Research and controversies

• Biallelic FLVCR1 disease is now viewed as a spectrum rather than a single ataxia, and the 2024 expansion to fetal akinesia and arthrogryposis has forced reclassification of variants previously reported as isolated retinal dystrophy.
• Pharmacological chaperones and substrate supplementation aimed at restoring FLVCR1 transport are in preclinical development, but none has entered a clinical trial for PCARP.
• Gene replacement with adeno-associated vectors is technically attractive for a retina and spinal cord disease, but the size of FLVCR1 and the need to reach dorsal column neurons remain unsolved delivery problems.
• Whether choline or heme transport is the dominant pathogenic function is unresolved, and this controversy determines which metabolic therapy is pursued first.
• The European Reference Network for rare neurological diseases and patient organisations for hereditary ataxia are building a natural history registry, which is the prerequisite for designing trials in a disorder with only about twenty published cases.